Transcription of WHO Drug Information
{{id}} {{{paragraph}}}
Pre-publication draft - page numbers are not for citation purposes 1 WHO drug Information Vol. 30, No. 1, 2016 ContentsConcept paper for comment3 A framework for risk-based identification of essential medicine products for local manufacturing in low- and middle-income countriesSafety of medicines24 The WHO Collaborating Centre for International drug Monitoring29 Look-alike sound-alike drug name confusion: trastuzumab emtansineQuality of medicines35 Quality of misoprostol productsPrequalification40 WHO rotational fellowships: an updateSafety news46 RestrictionsNicorandil: Use only as second-line angina treatment.
Concept paper for comment WHO Drug Information Vol. 30, No. 1, 2016 4 Pre-publication draft - page numbers are not for citation purposes affect the feasibility of the manufacturing process, including packaging and quality control testing, but also the overall quality assurance system of the manufacturer, as well as the
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}